633 related articles for article (PubMed ID: 6604610)
21. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
[TBL] [Abstract][Full Text] [Related]
22. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
23. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
Loos M; Heinz HP
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
[TBL] [Abstract][Full Text] [Related]
24. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
Rawal N; Pangburn MK
Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
Strunk RC; Giclas PC
J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
[No Abstract] [Full Text] [Related]
26. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase.
Burge J; Nicholson-Weller A; Austen KF
J Immunol; 1981 Jan; 126(1):232-5. PubMed ID: 6778916
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; van Es LA
Clin Exp Immunol; 1984 Jun; 56(3):614-20. PubMed ID: 6430610
[TBL] [Abstract][Full Text] [Related]
28. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
29. Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation.
García de Frutos P; Dahlbäck B
J Immunol; 1994 Mar; 152(5):2430-7. PubMed ID: 8133054
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
[TBL] [Abstract][Full Text] [Related]
31. Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers.
Zadura AF; Theander E; Blom AM; Trouw LA
Scand J Immunol; 2009 Apr; 69(4):374-80. PubMed ID: 19284503
[TBL] [Abstract][Full Text] [Related]
32. [Lupus and protein deficiencies of the classical complement pathway].
Weiss L; Maillet F; Kazatchkine M
Rev Prat; 1990 Sep; 40(21):1937-40. PubMed ID: 2237185
[TBL] [Abstract][Full Text] [Related]
33. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
Wouters D; Brouwer MC; Daha MR; Hack CE
Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.
Wouters D; Voskuyl AE; Molenaar ET; Dijkmans BA; Hack CE
Arthritis Rheum; 2006 Apr; 54(4):1143-50. PubMed ID: 16572449
[TBL] [Abstract][Full Text] [Related]
35. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
36. [Consumption hypocomplementemia: comparative value of haemolytic and protein estimations of the components of the classical pathway (author's transl)].
Roncato M; Vial MC; Maillet F; Peltier A
Nouv Presse Med; 1979 May; 8(20):1657-60. PubMed ID: 112575
[TBL] [Abstract][Full Text] [Related]
37. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
[TBL] [Abstract][Full Text] [Related]
38. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement.
Bijl M; Reefman E; Horst G; Limburg PC; Kallenberg CG
Ann Rheum Dis; 2006 Jan; 65(1):57-63. PubMed ID: 15919679
[TBL] [Abstract][Full Text] [Related]
39. A longitudinal study of circulating immune complexes, dna antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity.
Harkiss GD; Hazleman BL; Brown DL
J Clin Lab Immunol; 1979 Nov; 2(4):275-83. PubMed ID: 537024
[TBL] [Abstract][Full Text] [Related]
40. [Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases].
Takada K; Morishita M; Sugiura T; Suzuki M; Torii Y; Ichimura K; Hashigami H; Toshikawa K; Ina Y; Yamamoto M; Oyama A; Urata A
Gan No Rinsho; 1983 Apr; 29(4):A-19, 293-6. PubMed ID: 6602233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
